15
total announcements
BAFNAPH.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹1,070 Cr
P/E (TTM)
137.5
EPS (TTM)
₹3.29
52W Low
₹94.77
52W High
₹452.35
Dividend Yield
0.00%
Beta
0.07
Price / Book
11.1
Debt / Equity
38.9
Revenue (TTM)
₹143 Cr
Gross Margin
31.57%
Operating Margin
-3.38%
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialization of securities and listing on stock exchanges.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from October 01, 2026 till 48 Hours after the declaration of Un-audited Financial Results for the Quarter ending September 30, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has submitted the voting results of its 31st Annual General Meeting, which was held on September 11, 2026, through video conferencing. The meeting saw a total of 2,36,56,335 shares being voted, with all resolutions being passed with a majority.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited held its 31st Annual General Meeting (AGM) on September 11, 2026, through video conferencing. The meeting was conducted by Mrs. Ravichandran Chitra, Chairperson of the Board, and the proceedings were summarized. The company's financial performance for the year 2025-2026 was presented by Ms. S Hemalatha, Whole Time Director. The meeting was attended by the Board of Directors, Key Managerial Personnel, Statutory Auditors, Scrutinizer, and Secretarial Auditor. The company's financial statements for the year 2025-2026 were adopted, and the resolutions were passed through remote e-voting.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has published a copy of a newspaper publication confirming the dispatch of the notice of its 31st Annual General Meeting and the annual report for the financial year 2025-2026 in Business Standard and Makkal Kural on August 20, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of 31st Annual General Meeting of the Company to be held on September 11, 2026 along with the Annual Report for F.Y 2025-2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation for Book Closure & Cut off Date' for its 31st Annual General Meeting, which will be held on September 11, 2026, through Video Conferencing/OAVM. The Register of Members and Share Transfer Books will be closed from September 5 to September 11, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange regarding intimation for the 31st Annual General Meeting of the Company to be held on September 11, 2026. The meeting will be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The Register of Members and Share Transfer Books of the company will remain closed from September 5, 2026, to September 11, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a profit of INR 7.51 lakhs and earnings per equity share of INR 0.03. The company has also announced its 31st Annual General Meeting (AGM) to be held on September 11, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, along with the outcome of its Board Meeting held on August 11, 2026. The company reported a profit of INR 7.51 lakhs for the quarter, with a basic earnings per share of INR 0.03.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, confirming the dematerialization of securities and listing on stock exchanges.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has submitted a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, for the financial year ended on 31st March, 2026.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited announced the retirement of Mr. Navin Kumar as an Independent Director upon completion of his first term, effective June 22, 2026. Consequently, he will also cease to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The company has re-constituted these committees to ensure continued compliance with regulatory requirements. This is a routine change due to the expiry of a director's term.